Clinical Trial

Clinical Epidemiology in Contemporary Patients With Myelofibrosis.

Study acronym: ERNEST-3
Recruiting
View on ClinicalTrials.gov →
Summary
Multicenter retrospective and prospective European observational study. At each site, all consecutive patients with a 2016- or 2022 World Health Organization (WHO) confirmed diagnosis of myelofibrosis (MF) established from 01/01/2018 to 31/12/2027 will be enrolled into the study. Yearly follow-up updates will be scheduled until the end of data collection on 31/12/2028 or until the last available patient visit, whichever comes first. At least 1 year of follow-up will be ensured from the last patient enrolled.
Protocol Amendment History 2 changes
notable Trial sites reduced: 36 -> 27 locations 2026-07-10
notable Primary completion pushed: 2025-12-19 -> 2028-12-31 2026-07-10
Trial Details
NCT Number NCT06533813
Lead Sponsor FROM- Fondazione per la Ricerca Ospedale di Bergamo- ETS
Collaborators: GlaxoSmithKline
Conditions Myelofibrosis
Enrollment 617 participants
Start Date 2024-10-14
Primary Completion 2028-12-31 (estimated)
Study Completion 2028-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-07-09